
|Articles|October 26, 2012
Pharmaceutical Company to Pay $95M to Settle Allegations of Improper Drug Promotion
Advertisement
Boehringer Ingelheim Pharmaceuticals Inc. will pay $95 million to settle allegations that the company promoted three drugs for uses that were not medically accepted, the government announced Thursday.
The Justice Department said the three are the stroke-prevention drug Aggrenox, the chronic obstructive pulmonary disease drug Combivent and the high-blood-pressure drug Micardis.
Read the full story:
Source: The Washington Post
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Misinformation and Knowledge Gaps Undermine Vaccine Protection: Kristina Crothers, MD
2
Proactive MG Management Hinges on Better Coverage and Guidelines
3
Provider Shortages, Coverage, Cost Are Top Barriers to Care: CHEST 2025 Experts
4
With New OUD Diagnoses on the Rise, More Comprehensive Screenings Needed
5















































